Are you interested in short DAPT? Learn more…





The MASTER DAPT trial is and how is applies to short DAPT.




The MASTER DAPT trial is different to other clinical studies on short DAPT?




A short DAPT protocol fits with established guidelines?

Find Answers

Dr. Muramatsu is here to help you find some answers


Summary download for optimal DAPT protocol

The interview is in five parts and takes a total of 25 minutes to watch.      
A summary of the interview can be simple to confirm. 

You can download it in full here.



Behind the MASTER DAPT Trial

Learn how the MASTER DAPT trial differs to other short DAPT studies, as Dr. Muramatsu introduces the trial’s background and its main considerations.



Get insight


Short DAPT Guidelines across the Globe

Update your knowledge on recent short DAPT guidelines as Dr. Muramatsu looks at guidelines in US, Europe and Japan.


Get insight


How do you decide the duration for short DAPT?

Learn how to decide a short DAPT duration, as Dr. Muramatsu shares the short DAPT protocol at his hospital before and after the MASTER DAPT trial.


Get insight


What is the future of short DAPT?

Find out which tools can help improve patient wellbeing in short DAPT, as Dr. Muramatsu shares his opinion on the importance of drug eluting stents in a short DAPT procedure.

Read more about the MASTER DAPT Trial



Get the trial result

Sub-analysis: Complex PCI

Read the latest results from the MASTER DAPT Complex PCI sub-analysis.


Get the trial result

Sub-analysis: OAC

Read the summary report for the MASTER DAPT OAC sub-analysis result. 


Get the trial result

Summary of main trial 

Read the summary report of the MASTER DAPT main trial result.  


Product Characteristics

Our Ultimaster™ stent, used in the MASTER DAPT trial, has three innovative features which help support a short DAPT strategy.


1. Stent Flexibility

Flexible 80μm Cocr platform with optimal conformability to reduce mechanical stress on the vessel wall.


2. Gradient Coating Technology

Elastic gradient PDLLA-PCL short term polymer exposure mirrors biological response, promoting rapid vascular repair within 3-4 months.


3. Abluminal Coating Technology & Drug

Silorimus: Most proven drug on stents. Drug release matches biological response targeted abluminal drug delivery. Low Nominal drug dose: 3.9μg/mm or 0.7μg/mm2




Terumo’s proprietary bioresorbable polymer coating and two-link design help facilitate smoother access. Discover how the UltimasterTM stent can ensure optimal deliverability and potentially shortened DAPT time.

Learn more about Ultimaster™ 

Ultimaster™ product (image)

New MASTER DAPT Webinars to Optimize your DAPT StrategyNew MASTER DAPT Webinars to Optimize your DAPT Strategy

The results of the MASTER DAPT study proved the non-inferiority of short DAPT, and helped bridge the current knowledge gap on DAPT duration in high bleeding risk patients. Understand the potential impact on DAPT guidelines and how to select the optimal DAPT duration for your patients with our collection of MASTER DAPT webinars from around the globe.

Explore more


Event related to MASTER DAPT(image)
MASTER DAPT trial is sponsored by the European Cardiovascular Research Institute (ECRI, Rotterdam, The Netherlands) and supported with a restricted research grant by Terumo Europe. The study is managed by global CROs and data management group (CERC, Paris, France, Cardialysis, Rotterdam, The Netherlands, CV quest. Co. Ltd., Tokyo, Japan and CTU, Bern, Switzerland).